AAPL315.34-0.88 (-0.28%) ▼|ABBV250.91+2.13 (+0.86%) ▲|ABT104.61-0.64 (-0.61%) ▼|ACN175.94+0.10 (+0.06%) ▲|ADBE250.87-4.00 (-1.57%) ▼|AMAT456.67-12.19 (-2.60%) ▼|AMD509.74-11.36 (-2.18%) ▼|AMGN390.18-1.09 (-0.28%) ▼|AMT174.98-0.60 (-0.34%) ▼|AMZN251.14-1.26 (-0.50%) ▼|AVGO359.25-5.13 (-1.41%) ▼|AXP321.15-0.65 (-0.20%) ▼|BA207.29+0.81 (+0.39%) ▲|BAC62.61-0.08 (-0.13%) ▼|BKNG173.65+0.22 (+0.13%) ▲|BLK1,067.32-5.20 (-0.48%) ▼|BMY64.39-0.02 (-0.03%) ▼|BNY162.60+0.03 (+0.02%) ▲|BRK-B507.32+0.56 (+0.11%) ▲|C138.00+0.19 (+0.14%) ▲|CAT809.00-7.05 (-0.86%) ▼|CL88.66+0.65 (+0.73%) ▲|CMCSA24.74+0.15 (+0.61%) ▲|COF209.00-1.95 (-0.92%) ▼|COP137.89+1.28 (+0.94%) ▲|COST910.45+7.85 (+0.87%) ▲|CRM244.22+0.02 (+0.01%) ▲|CSCO109.31-0.12 (-0.11%) ▼|CVS96.74+1.36 (+1.42%) ▲|CVX215.32+1.50 (+0.70%) ▲|DE676.67-0.62 (-0.09%) ▼|DHR200.69-4.30 (-2.10%) ▼|DIS104.09-0.09 (-0.08%) ▼|DUK120.79+0.35 (+0.29%) ▲|EMR148.07-2.33 (-1.55%) ▼|FDX308.33-0.90 (-0.29%) ▼|GD353.93+1.25 (+0.35%) ▲|GE323.99-1.45 (-0.45%) ▼|GEV937.18-13.43 (-1.41%) ▼|GILD145.60-0.06 (-0.04%) ▼|GM84.25+0.47 (+0.56%) ▲|GOOG327.17-1.21 (-0.37%) ▼|GOOGL329.11-1.54 (-0.47%) ▼|GS1,020.92-8.44 (-0.82%) ▼|HD306.26-4.23 (-1.36%) ▼|HON202.20-2.74 (-1.33%) ▼|IBM236.52-3.45 (-1.44%) ▼|INTC101.21-5.03 (-4.73%) ▼|INTU311.27-2.67 (-0.85%) ▼|ISRG349.01-4.23 (-1.20%) ▼|JNJ269.88+2.69 (+1.00%) ▲|JPM353.34-1.35 (-0.38%) ▼|KO88.65+1.07 (+1.22%) ▲|LIN466.67+0.02 (+0.00%) ▲|LLY1,130.15+5.89 (+0.52%) ▲|LMT526.16+1.67 (+0.32%) ▲|LOW196.14-2.47 (-1.24%) ▼|LRCX303.62-12.22 (-3.87%) ▼|MA564.85-2.77 (-0.49%) ▼|MCD254.89+1.35 (+0.53%) ▲|MDLZ62.39-0.04 (-0.06%) ▼|MDT91.36-0.55 (-0.60%) ▼|META653.24-0.45 (-0.07%) ▼|MMM162.71-1.71 (-1.04%) ▼|MO68.81+0.90 (+1.32%) ▲|MRK147.25-0.34 (-0.23%) ▼|MS214.48-0.87 (-0.40%) ▼|MSFT488.14-3.51 (-0.71%) ▼|MU987.89-39.88 (-3.88%) ▼|NEE83.02+0.35 (+0.42%) ▲|NFLX75.10-0.93 (-1.22%) ▼|NKE36.97-0.39 (-1.03%) ▼|NOW131.90+0.79 (+0.60%) ▲|NVDA219.19-4.48 (-2.00%) ▼|ORCL157.72-4.00 (-2.48%) ▼|PEP136.87+0.18 (+0.13%) ▲|PFE27.68-0.11 (-0.38%) ▼|PG143.04+0.37 (+0.26%) ▲|PLTR165.81-3.72 (-2.19%) ▼|PM189.72+4.03 (+2.17%) ▲|QCOM171.81-4.59 (-2.60%) ▼|RTX197.28-0.30 (-0.15%) ▼|SBUX99.90-0.14 (-0.14%) ▼|SCHW107.02+0.48 (+0.45%) ▲|SO88.63+0.28 (+0.32%) ▲|SPG206.05+1.42 (+0.69%) ▲|T25.65+0.49 (+1.95%) ▲|TMO599.60-6.57 (-1.08%) ▼|TMUS178.45+1.11 (+0.63%) ▲|TSLA361.49-6.33 (-1.72%) ▼|TXN257.18-4.41 (-1.69%) ▼|UBER69.68-1.43 (-2.00%) ▼|UNH398.24+5.17 (+1.31%) ▲|UNP287.53+2.74 (+0.96%) ▲|UPS99.38+0.16 (+0.16%) ▲|USB62.24+0.11 (+0.17%) ▲|V366.64-0.94 (-0.26%) ▼|VZ50.51+0.75 (+1.51%) ▲|WFC89.75+0.07 (+0.07%) ▲|WMT107.00+1.17 (+1.10%) ▲|XOM164.83+0.57 (+0.34%) ▲|AAPL315.34-0.88 (-0.28%) ▼|ABBV250.91+2.13 (+0.86%) ▲|ABT104.61-0.64 (-0.61%) ▼|ACN175.94+0.10 (+0.06%) ▲|ADBE250.87-4.00 (-1.57%) ▼|AMAT456.67-12.19 (-2.60%) ▼|AMD509.74-11.36 (-2.18%) ▼|AMGN390.18-1.09 (-0.28%) ▼|AMT174.98-0.60 (-0.34%) ▼|AMZN251.14-1.26 (-0.50%) ▼|AVGO359.25-5.13 (-1.41%) ▼|AXP321.15-0.65 (-0.20%) ▼|BA207.29+0.81 (+0.39%) ▲|BAC62.61-0.08 (-0.13%) ▼|BKNG173.65+0.22 (+0.13%) ▲|BLK1,067.32-5.20 (-0.48%) ▼|BMY64.39-0.02 (-0.03%) ▼|BNY162.60+0.03 (+0.02%) ▲|BRK-B507.32+0.56 (+0.11%) ▲|C138.00+0.19 (+0.14%) ▲|CAT809.00-7.05 (-0.86%) ▼|CL88.66+0.65 (+0.73%) ▲|CMCSA24.74+0.15 (+0.61%) ▲|COF209.00-1.95 (-0.92%) ▼|COP137.89+1.28 (+0.94%) ▲|COST910.45+7.85 (+0.87%) ▲|CRM244.22+0.02 (+0.01%) ▲|CSCO109.31-0.12 (-0.11%) ▼|CVS96.74+1.36 (+1.42%) ▲|CVX215.32+1.50 (+0.70%) ▲|DE676.67-0.62 (-0.09%) ▼|DHR200.69-4.30 (-2.10%) ▼|DIS104.09-0.09 (-0.08%) ▼|DUK120.79+0.35 (+0.29%) ▲|EMR148.07-2.33 (-1.55%) ▼|FDX308.33-0.90 (-0.29%) ▼|GD353.93+1.25 (+0.35%) ▲|GE323.99-1.45 (-0.45%) ▼|GEV937.18-13.43 (-1.41%) ▼|GILD145.60-0.06 (-0.04%) ▼|GM84.25+0.47 (+0.56%) ▲|GOOG327.17-1.21 (-0.37%) ▼|GOOGL329.11-1.54 (-0.47%) ▼|GS1,020.92-8.44 (-0.82%) ▼|HD306.26-4.23 (-1.36%) ▼|HON202.20-2.74 (-1.33%) ▼|IBM236.52-3.45 (-1.44%) ▼|INTC101.21-5.03 (-4.73%) ▼|INTU311.27-2.67 (-0.85%) ▼|ISRG349.01-4.23 (-1.20%) ▼|JNJ269.88+2.69 (+1.00%) ▲|JPM353.34-1.35 (-0.38%) ▼|KO88.65+1.07 (+1.22%) ▲|LIN466.67+0.02 (+0.00%) ▲|LLY1,130.15+5.89 (+0.52%) ▲|LMT526.16+1.67 (+0.32%) ▲|LOW196.14-2.47 (-1.24%) ▼|LRCX303.62-12.22 (-3.87%) ▼|MA564.85-2.77 (-0.49%) ▼|MCD254.89+1.35 (+0.53%) ▲|MDLZ62.39-0.04 (-0.06%) ▼|MDT91.36-0.55 (-0.60%) ▼|META653.24-0.45 (-0.07%) ▼|MMM162.71-1.71 (-1.04%) ▼|MO68.81+0.90 (+1.32%) ▲|MRK147.25-0.34 (-0.23%) ▼|MS214.48-0.87 (-0.40%) ▼|MSFT488.14-3.51 (-0.71%) ▼|MU987.89-39.88 (-3.88%) ▼|NEE83.02+0.35 (+0.42%) ▲|NFLX75.10-0.93 (-1.22%) ▼|NKE36.97-0.39 (-1.03%) ▼|NOW131.90+0.79 (+0.60%) ▲|NVDA219.19-4.48 (-2.00%) ▼|ORCL157.72-4.00 (-2.48%) ▼|PEP136.87+0.18 (+0.13%) ▲|PFE27.68-0.11 (-0.38%) ▼|PG143.04+0.37 (+0.26%) ▲|PLTR165.81-3.72 (-2.19%) ▼|PM189.72+4.03 (+2.17%) ▲|QCOM171.81-4.59 (-2.60%) ▼|RTX197.28-0.30 (-0.15%) ▼|SBUX99.90-0.14 (-0.14%) ▼|SCHW107.02+0.48 (+0.45%) ▲|SO88.63+0.28 (+0.32%) ▲|SPG206.05+1.42 (+0.69%) ▲|T25.65+0.49 (+1.95%) ▲|TMO599.60-6.57 (-1.08%) ▼|TMUS178.45+1.11 (+0.63%) ▲|TSLA361.49-6.33 (-1.72%) ▼|TXN257.18-4.41 (-1.69%) ▼|UBER69.68-1.43 (-2.00%) ▼|UNH398.24+5.17 (+1.31%) ▲|UNP287.53+2.74 (+0.96%) ▲|UPS99.38+0.16 (+0.16%) ▲|USB62.24+0.11 (+0.17%) ▲|V366.64-0.94 (-0.26%) ▼|VZ50.51+0.75 (+1.51%) ▲|WFC89.75+0.07 (+0.07%) ▲|WMT107.00+1.17 (+1.10%) ▲|XOM164.83+0.57 (+0.34%) ▲|
22.8 C
New York
Thursday, September 10, 2026

Tag: stage

newssourceFORcompanyinformationcontent1releasesmarket

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH 
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update

COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company’s listing on the TSX

Hesai Group Reports Second Quarter 2025 Unaudited Financial Results

Quarterly net revenues were RMB706.4 million (US$98.6 million)1
Quarterly lidar shipments were 352,095 units
Quarterly net income was RMB44.1 million (US$6.2 million)

East Side Games Group Reports Q2 2025 Financial Results

VANCOUVER, BC, Aug. 14, 2025 /CNW/ - East Side Games Group (TSX: EAGR) (OTC: EAGRF) ("ESGG" or the "Company"), today announced its financial results...

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in...

NANO Nuclear Reports Third Fiscal Quarter 2025 Financial Results and Provides Business Update

New York, N.Y., Aug. 14, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today reported its third fiscal quarter financial results and provided a business update.

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3...

Roofing Contractor Business Loans: ROK Financial Speeds Up Working Capital Access Ahead of Storm Season

Flexible financing options for roofing contractors, including no credit check programs, to prepare crews, materials, and equipment ahead of Storm Season 2025. 
Flexible financing options for roofing contractors, including no credit check programs, to prepare crews, materials, and equipment ahead of Storm Season 2025.

Emmaus Life Sciences Reports Quarterly Financial Results

TORRANCE, Calif., Aug. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell...

LYNO AI Early Bird Presale Exceeds 265K Tokens Sold as Price Increase Approaches

ROAD TOWN, British Virgin Islands, Aug. 14, 2025 (GLOBE NEWSWIRE) -- LYNO AI today announced that its Early Bird presale phase has achieved strong momentum, with over 265,000 tokens sold in a short span of time. Currently priced at $0.050 per token, this stage has attracted significant attention from the cryptocurrency community due to LYNO AI’s innovative offerings and favorable entry point.

Mercury Marine Captures 50% Share of Outboards on display at Sydney International Boat Show

SYDNEY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Mercury Marine, a division of Brunswick Corporation (NYSE: BC), accounted for 50% of all outboard engines on display at the Sydney International Boat Show, which opened Thursday at Sydney Olympic Park. Mercury also showcased more than double the number of outboards compared to its nearest competitor during the event.

Base Molecular Resonance™ Technologies Names Bryan Adams as Chief Marketing Officer

Executive Strategist to Lead Global Brand, Market Growth, and Cross-Vertical Commercialization for Quantum Detection Pioneer STUART, Fla., Aug. 14, 2025 /PRNewswire/ -- Base Molecular Resonance™...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStage

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers